Anonymous
Guest
Anonymous
Guest
Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision
Bethesda, MD, June 29, 2012 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that the International Court of Arbitration, International Chamber of Commerce (ICC) has notified the Company of a change in the anticipated date of the decision related to the Company’s demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceutical Company Limited, or Takeda. The ICC has extended the date from June 29, 2012 to July 31, 2012.
Sucampo is eager to receive the ICC’s decision as quickly as possible, and we continue our substantial planning in anticipation of a favorable award. Through these efforts, we look forward to increasing patient and healthcare provider access to AMITIZA® in the event of a favorable outcome.
Bethesda, MD, June 29, 2012 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that the International Court of Arbitration, International Chamber of Commerce (ICC) has notified the Company of a change in the anticipated date of the decision related to the Company’s demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceutical Company Limited, or Takeda. The ICC has extended the date from June 29, 2012 to July 31, 2012.
Sucampo is eager to receive the ICC’s decision as quickly as possible, and we continue our substantial planning in anticipation of a favorable award. Through these efforts, we look forward to increasing patient and healthcare provider access to AMITIZA® in the event of a favorable outcome.